Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6323071042
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001J1BQ86
NTRA
Natera Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $PLNG
NAME
Natera Inc
ISIN
US6323071042
TICKER
NTRA
MIC
XNAS
REUTERS
NTRA.OQ
BLOOMBERG
NTRA US
Mi., 05.08.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of the Signatera test in muscle-invasive bladder cancer (MIBC) as a companion diagnostic (CDx). The submission advances Natera’s growi...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2026, after the market closes on August 6, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Info...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 22.07.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to b...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Fr., 17.07.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 09.07.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR). The IVDR represents one of the world’s most rigorous regulatory frameworks for in vitro diagnostic medical devices, r...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 06.07.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease (MRD) test, in patients with resected colorectal liver metastases (CRLM). The data was also presented as an oral present...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 29.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Natera
US6323071042

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 24.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).This approval supports the use of Signatera for patients with colorectal cancer (CRC) in the adjuvant setting and makes Signatera the fir...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 24.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This approval supports the use of Signatera for patients with colorectal cancer (CRC) in the adjuvant setting and makes Signatera the...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 23.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Pro...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic coll...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 03.06.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company’s board of directors. “Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board,” said Mat...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecula...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer. The current standard of care recommend...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 26.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company’s novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL. Together with its collaborators, Natera will demonstrate unmatched scale in evid...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milestone in the company’s continued growth and mission to improve outcomes for patients with cancer and other serious diseases. At its North Austin headquarters campus, Natera will unve...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 20.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. EXPAND is a prospective, blinded, multi-site clinical trial designed to study Natera’s Fetal Focus single-gene...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 15.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of bl...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%....
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Informati...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academi...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera’s litigation with ArcherDx and Invitae. In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera o...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, CA. Th...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a publication in Clinical Cancer Research showing that Signatera was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery. While pET can be an alternative...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC). ASCC: publicat...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Natera
US6323071042

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By integrating methylation signatures (epigenetic signatures) into its whole-genome platform, MyOme is moving beyo...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay designed to significantly improve the detection of rare diseases. Natera is presenting on Zenith’s unique platform and performance at the 2026 American Col...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (M...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial Highlights Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Data was recently presented in an oral plenary at the 2026 MHNCS. Approximately 73K patients are diagnosed with head an...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market closes on Feb. 26, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call I...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Fr., 06.02.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company’s non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications. Preeclampsia affects approxi...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatmen...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 28.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients. Positive results would...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center (OSU-WMC), was initiated to explore whether donor-derived cell-free DNA (dd-cfDNA) sur...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay (tfMRD) in colorectal cancer (CRC). The peer-reviewed publication builds upon data that was previously presented at the...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026. EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera’s propr...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 13.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to extend the company’s leadership in oncology. The new multi-modal model will integrate longitudinal ctDNA and clinical data with digita...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal AI foundation model platform and expand applications across precision medicine. Under the collaboration, Natera will integrate its unique longitudinal an...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following: Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quar...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 06.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place January 8-10, 2026. A new analysis will be presented from the randomized, double-b...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 05.01.2026       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s expanded 21-gene Fetal Focus single gene non-invasive prenatal test (sgNIPT), supported by new findings from the blinded prospective EXPAND clinical trial. Results from this analysis demonstrate the test’s ability to detect...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Mo., 22.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment c...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Canc...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Di., 16.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications. The study examined how Signatera can refine risk assessment in patients with early-stage breast cancer whose tum...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study, which is a multicenter, phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-)...
Zur Nachricht
Natera
Charts & Research Termsheets Terminal
Permalink